Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720)

Excerpt from the Press Release:

CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the publication of data from its Phase 1 clinical trial, which assessed the intrapulmonary pharmacokinetics (PK) of SPR719. The full manuscript, titled “Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers” was published ahead of print in Antimicrobial Agents and Chemotherapy. A copy of the paper can be accessed here.

SPR720 is an oral, chemically stable phosphate ester prodrug that is converted rapidly in vivo to SPR719, the active moiety. SPR719 targets the ATPase site of DNA gyrase B in mycobacteria, a mechanism that is distinct from that of other antibiotics in use for Non Tuberculous Mycobacterial- Pulmonary Disease (NTM-PD).

“The Phase 1 study is part of a series of studies Spero is conducting in order to explore the potential of SPR720 as a treatment for NTM-PD,” said Sath Shukla, President and CEO of Spero. “Effective oral therapy for NTM lung disease requires adequate uptake into the pulmonary epithelial lining fluid and alveolar macrophages, where mycobacteria reside and proliferate. The results of this Phase 1 study suggest that SPR719 (the active moiety of SPR720) had significant lung uptake and enhanced concentrations in these compartments.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release